Human epididymis protein 4 (HE4) and ovarian cancer prognosis
Human epididymis protein 4 (HE4) and ovarian cancer prognosis
复制标题
DOI：
10.1016/j.ygyno.2012.09.003
复制
发表时间：
2012-12-01
影响因子：
4.7
通讯作者：
Bairati, Isabelle
中科院分区：
文献类型：
--
作者：
Trudel, Dominique;Tetu, Bernard;Bairati, Isabelle
目标。一项队列研究评估了术前血浆HE4水平是否可以预测卵巢癌(OC)患者的死亡(主要终点)和进展(次要终点)的发生。1998年至2006年，我们在加拿大魁北克省楚克-L酒店的大学医院招募了136名新诊断为任何FIGO阶段DC的女性。HE4的测定采用雅培的建筑师HE4测定法。死亡日期是通过与魁北克死亡档案的记录联系获得的。按照妇科癌症小组的建议，使用CA-125或RECIST标准对进展进行评估。用COX比例风险回归模型估计死亡和进展的调整危险比(HR)及其95%可信区间(CI)。术前HE4水平与所有DC标准预后因素密切相关。HE4水平随年龄(p=0.02)、FIGO分期(p<0.05)的增加而显著升高。
Objective. A cohort study was conducted to evaluate whether preoperative plasma HE4 levels could predict the occurrence of death (primary endpoint) and progression (secondary endpoint) in women with ovarian cancer (OC).Methods. Between 1998 and 2006, we recruited 136 women newly diagnosed with DC of any FIGO stage at the University Hospital, CHUQ-L'Hotel-Dieu de Quebec, Canada. HE4 was measured using the Abbott's ARCHITECT HE4 assay. Dates of death were obtained by record linkage with the Quebec mortality files. Progression was evaluated using the CA-125 or the RECIST criteria, as recommended by the Gynecology Cancer Intergroup. Adjusted hazard ratios (HR) of death and progression, as well as their 95% confidence intervals (Cl), were estimated using the Cox proportional hazard regression model.Results. Preoperative levels of HE4 were strongly associated with all DC standard prognostic factors. HE4 levels increased significantly with age (p=0.02), FIGO stage (p